<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9784" href="/d/html/9784.html" rel="external">see "Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Drug information"</a> and <a class="drug drug_patient" data-topicid="11882" href="/d/html/11882.html" rel="external">see "Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F210866"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pneumovax 23</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914132"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pneumo 23;</li>
<li>Pneumovax 23</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061157"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Inactivated Bacteria</span></li></ul></div>
<div class="block dop drugH1Div" id="F210874"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b> Children ≥2 years and Adolescents with specified underlying medical conditions: IM, SubQ: 0.5 mL as a single dose; immunization with pneumococcal conjugate vaccine (PCV13) should be completed prior to pneumococcal polysaccharide vaccine (PPSV23) as recommended. The minimum interval between PCV13 and PPSV23 is 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20498180','lexi-content-ref-26334788','lexi-content-ref-21150868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20498180','lexi-content-ref-26334788','lexi-content-ref-21150868'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3085958f-2428-4e7a-a4ca-b6cab8914e65">Revaccination</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Revaccination: </b> Children ≥2 and Adolescents with functional or anatomic asplenia, those who are immunocompromised, and others with high-risk medical conditions [see guidelines for specific details]: One revaccination dose ≥5 years after the first dose of PPSV23.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153890"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153891"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F210868"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9784" href="/d/html/9784.html" rel="external">see "Pneumococcal polysaccharide vaccine (23-valent) (PPSV23): Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note:</b> According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f494398e-6892-4105-93a3-415a509feae1">Pneumococcal disease prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal disease prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CDC/ACIP recommendations:</b>
<b>PPSV23:</b>
<b>IM, SUBQ: </b>0.5 mL/dose; see the following recommendations based on age, prior pneumococcal vaccination, and comorbid conditions/risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37669242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37669242'])">Ref</a></span>). For additional guidance, the CDC recommends using the <i>PneumoRecs VaxAdvisor</i> (mobile app or web version: <a href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fagegroup.html&amp;token=S7NJDVC075c2ynIRAXnAPvQ1hfzYoEzrZ6Csny1KNFSbioH1EnyyHwxKKgy6EV9RIAIo5zF9QhQU%2Bch6fnIklA%3D%3D&amp;TOPIC_ID=12948" target="_blank">https://www2a.cdc.gov/vaccines/m/pneumo/agegroup.html</a>).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Pneumococcal Vaccination for Patients 19 to 64 Years of Age with Certain Chronic Health Conditions or Other Risk Factors<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">Prior pneumococcal vaccination</p></th>
<th align="center">
<p style="text-indent:0em;">Option A<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Option B<sup>d</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Includes alcohol use disorder, chronic heart/liver/lung disease, cigarette smoking, diabetes mellitus.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Vaccine abbreviations: Pneumococcal conjugate vaccine 20-valent = PCV20; Pneumococcal conjugate vaccine 15-valent = PCV15; Pneumococcal conjugate vaccine 13-valent = PCV13; Pneumococcal polysaccharide vaccine 23-valent = PPSV23. Refer to individual monographs for additional information.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> PCV20 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> PCV15 and PPSV23 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e</sup> Also applies to patients who previously received PCV7 (at any age) but no other pneumococcal vaccines or unknown vaccination status.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>f </sup>Review recommendations again when patient turns 65 years of age.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">None<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">PCV20</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 followed by PPSV23 ≥1 year later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PPSV23 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 administered ≥1 year later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PPSV23 administered ≥1 year later<sup>f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 and PPSV23</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">No additional pneumococcal vaccine at this time.<sup>f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV15 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">PPSV23 ≥1 year later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV20 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">No additional pneumococcal vaccine at this time.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Pneumococcal Vaccination for Patients 19 to 64 Years of Age with Specified Immunocompromising Conditions<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Prior pneumococcal vaccination</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option A<sup>c</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option B<sup>d</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Includes asplenia (congenital or acquired), chronic renal failure, generalized malignancy, HIV infection, Hodgkin disease, immunodeficiencies (congenital or acquired), immunosuppression (iatrogenic, including immunosuppressive therapies), leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease and other hemoglobinopathies, solid organ transplant. Excludes hematopoietic cell transplant (HCT).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Vaccine abbreviations: Pneumococcal conjugate vaccine 20-valent = PCV20; Pneumococcal conjugate vaccine 15-valent = PCV15; Pneumococcal conjugate vaccine 13-valent = PCV13; Pneumococcal polysaccharide vaccine 23-valent = PPSV23. Refer to individual monographs for additional information.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> PCV20 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> PCV15 and PPSV23 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>Also applies to patients who previously received PCV7 (at any age) but no other pneumococcal vaccines or unknown vaccination status.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>f </sup>Review recommendations again when patient turns 65 years of age.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">None<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">PCV20</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 followed by PPSV23 ≥8 weeks later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PPSV23 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 administered ≥1 year later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PPSV23 administered ≥8 weeks later followed by another PPSV23 dose ≥5 years later<sup>f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 and 1 dose of PPSV23</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥5 years later</p></td>
<td align="center">
<p style="text-indent:0em;">PPSV23 administered ≥5 years later<sup>f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 and 2 doses of PPSV23</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥5 years later</p></td>
<td align="center">
<p style="text-indent:0em;">No additional pneumococcal vaccine at this time<sup>f</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV15 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">PPSV23 administered ≥8 weeks later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV20 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">No additional pneumococcal vaccine at this time.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Pneumococcal Vaccination for Patients 19 to 64 Years of Age with a Cochlear Implant or Cerebrospinal Fluid Leak<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Prior pneumococcal vaccination</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option A<sup>b</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option B<sup>c</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Vaccine abbreviations: Pneumococcal conjugate vaccine 20-valent = PCV20; Pneumococcal conjugate vaccine 15-valent = PCV15; Pneumococcal conjugate vaccine 13-valent = PCV13; Pneumococcal polysaccharide vaccine 23-valent = PPSV23. Refer to individual monographs for additional information.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> PCV20 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> PCV15 and PPSV23 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> Also applies to patients who previously received PCV7 (at any age) but no other pneumococcal vaccines or unknown vaccination status.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>Review recommendations again when patient turns 65 years of age.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">None<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;">PCV20</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 followed by PPSV23 ≥8 weeks later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PPSV23 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 administered ≥1 year later</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 only</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥1 year later</p></td>
<td align="center">
<p style="text-indent:0em;">PPSV23 administered ≥8 weeks later<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV13 and 1 dose of PPSV23</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥5 years later</p></td>
<td align="center">
<p style="text-indent:0em;">No additional pneumococcal vaccine at this time<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV15 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">PPSV23 administered ≥8 weeks later<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">PCV20 only</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">No pneumococcal vaccine at this time.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Pneumococcal Vaccination for Patients ≥19 Years of Age after HCT<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Prior pneumococcal vaccination</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option A<sup>c</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Option B<sup>d</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Vaccine abbreviations: Pneumococcal conjugate vaccine 20-valent = PCV20; Pneumococcal conjugate vaccine 15-valent = PCV15; Pneumococcal conjugate vaccine 13-valent = PCV13; Pneumococcal polysaccharide vaccine 23-valent = PPSV23. Refer to individual monographs for additional information.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Four doses of a pneumococcal vaccine after HCT are needed to complete the series.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> PCV20 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> PCV15 and PPSV23 available.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>Whichever time point is later; consult with transplant providers for optimal timing.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">None after HCT</p></td>
<td align="center">
<p style="text-indent:0em;">Three doses of PCV20 administered 4 weeks apart beginning 3 to 6 months after HCT; administer fourth dose of PCV20 ≥6 months after third dose of PCV20 or ≥1 year from HCT<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Three doses of PCV15 administered 4 weeks apart beginning 3 to 6 months after HCT, followed by PPSV23 ≥1 year from HCT (administer PCV15 in place of PPSV23 if patient has chronic GVHD).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 dose of PCV13 or PCV 15 after HCT</p></td>
<td align="center">
<p style="text-indent:0em;">Two doses of PCV20 administered 4 weeks apart beginning 4 weeks after last PCV13 or PCV15 dose;<i></i>administer third dose of PCV20 ≥6 months after second dose of PCV20 or ≥1 year from HCT<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Two doses of PCV15 administered 4 weeks apart beginning 4 weeks after last PCV13 or PCV15 dose; administer PPSV23 ≥1 year from HCT (administer PCV15 in place of PPSV23 if patient has chronic GVHD<i>).</i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 doses of PCV13 or PCV 15 after HCT</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered 4 weeks after last PCV13 or PCV15 dose; administer second dose of PCV20 ≥6 months after first dose of PCV20 or ≥1 year from HCT<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">PCV15 administered 4 weeks after last PCV13 or PCV15 dose, followed by PPSV23 ≥1 year from HCT (administer PCV15 in place of PPSV23 if patient has chronic GVHD).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 doses of PCV13 or PCV 15 after HCT</p></td>
<td align="center">
<p style="text-indent:0em;">PCV20 administered ≥6 months after last dose of PCV13 or PCV15 or ≥1 year from HCT<sup>e</sup></p></td>
<td align="center">
<p style="text-indent:0em;">PPSV23 ≥1 year from HCT (administer PCV15 in place of PPSV23 if patient has chronic GVHD).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<b>Canadian recommendations:</b> The Canadian National Advisory Committee on Immunization (NACI) provides different recommendations as compared to the CDC; see NACI recommendations for details.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990355"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50987728"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline"> There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F210848"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (16% to 35%), induration at injection site (≤40%), local soreness/soreness at injection site (≤77%), pain at injection site (≤77%), swelling at injection site (≤40%; including peripheral edema in injected extremity), tenderness at injection site (≤77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (≤18%), headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤18%), myalgia (12% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses (1%), pruritus (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (1%), dyspepsia (1%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Neck pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, erythema multiforme, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased, hemolytic anemia (in patients with other hematologic disorders), leukocytosis, lymphadenitis, lymphadenopathy, thrombocytopenia (in patients with stabilized immune thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, nonimmune anaphylaxis, serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Tissue necrosis at injection site, warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Guillain-Barré syndrome, malaise, nerve root disorder, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, decreased range of motion (limb)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Febrile seizure</p></div>
<div class="block coi drugH1Div" id="F210859"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe allergic reaction (eg, anaphylactic/anaphylactoid reaction) to pneumococcal vaccine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F210846"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinitis) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severely compromised cardiovascular function where a systemic reaction may pose a significant risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Patients with HIV should be vaccinated as soon as possible following confirmation of the diagnosis (CDC/ACIP 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrospinal fluid (CSF) leaks: Vaccination may not be as effective in patients with chronic CSF leaks due to congenital lesions, skull fractures, or neurosurgical procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pneumococcal meningitis: Pneumococcal vaccine may not be effective in preventing pneumococcal meningitis in persons who have chronic cerebrospinal fluid leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with severe pulmonary disease where a systemic reaction may pose a significant risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Splenectomy: Patients who will undergo splenectomy should also be vaccinated at least 2 weeks prior to surgery, if possible (IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia purpura: May cause relapse in patients with stable idiopathic thrombocytopenia purpura.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist (ACIP [Kroger 2023]). If a person has not received any pneumococcal vaccine or if pneumococcal vaccination status is unknown, PPSV23 should be administered as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antibiotic prophylaxis: This vaccine does not replace the need for penicillin (or other antibiotic) prophylaxis against pneumococcal infection. In persons who require penicillin (or other antibiotic) prophylaxis against pneumococcal infection, such prophylaxis should not be discontinued after vaccination with pneumococcal vaccine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; (IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Children: Pneumococcal vaccine is not approved for use in children &lt;2 years. Children in this age group do not develop an effective immune response to the capsular types contained in this polysaccharide vaccine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cochlear implants: Patients who will undergo cochlear implant placement should be vaccinated at least 2 weeks prior to surgery, if possible (IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Postmarketing reports of adverse effects in elderly patients, especially those with comorbidities, have been significant enough to require hospitalization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014). Vaccination does not replace the need for antibiotic prophylaxis against pneumococcal infection when otherwise required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878594"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Not recommended for use in infants and children &lt;2 years of age.  </p></div>
<div class="block foc drugH1Div" id="F210854"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">Pneumovax 23: 25 mcg each of 23 capsular polysaccharide isolates/0.5 mL (0.5 mL, 2.5 mL) [contains phenol]</p></div>
<div class="block geq drugH1Div" id="F210842"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323702"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Pneumovax 23 Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg/0.5 mL (per 0.5 mL): $140.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613608"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Administer SUBQ or IM either the anterolateral aspect of the thigh or the deltoid muscle; not for IV or intradermal administration. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If purchased under CDC contract, US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F210865"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block meg drugH1Div" id="F25734159"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) should be provided to the patient/caregiver before administering each dose of this vaccine. If purchased under CDC contract, the VIS must be provided and the VIS edition date and date it was provided to the patient/caregiver should be recorded. VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fppv.html&amp;token=Jo%2BTJVXtdtuhdib4J4tH07%2BEIwFHUeqRvYcPDXCbODI0FWrK7%2Fug2ZC5FmdmKrMO0jWpRtWJI8jVsXBiHo033w%3D%3D&amp;TOPIC_ID=12948" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53568411"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To provide immunization against pneumococcal disease caused by serotypes included in the vaccine (FDA approved in ages ≥2 years and adults).</p>
<p style="text-indent:0em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for patients with the following underlying medical conditions (ACIP [Kobayashi 2015]; CDC/ACIP 59[34] 2010; CDC/ACIP 61[40] 2012; CDC/ACIP [Nuorti 2010]; CDC/ACIP [Tomczyk 2014]):</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised children ≥2 years, adolescents, and adults ≤64 years with congenital or acquired immunodeficiency (includes B or T cell deficiency, complement deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">• Children ≥2 years, adolescents, and adults 19 to 64 years with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompetent children ≥2 years and adolescents with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompetent adults 19 to 64 years with chronic heart disease (including heart failure and cardiomyopathies; excluding hypertension), chronic lung disease (including COPD, emphysema, and asthma), diabetes, cerebrospinal fluid leaks, cochlear implants, alcoholism, chronic liver disease, cirrhosis, and cigarette smokers</p>
<p style="text-indent:-2em;margin-left:4em;">• All adults ≥65 years</p></div>
<div class="block mst drugH1Div" id="F7914139"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pneumococcal 23-valent polysaccharide vaccine (Pneumovax 23) may be confused with pneumococcal 13-valent conjugate vaccine (Prevnar 13), pneumococcal 15-valent conjugate vaccine (Vaxneuvance, PCV15), and pneumococcal 20-valent conjugate vaccine (Prevnar 20, PCV20).</p>
<p style="text-indent:-2em;margin-left:4em;">PPSV23 (pneumococcal 23-valent polysaccharide vaccine) may be confused with PCV13 (pneumococcal 13-valent conjugate vaccine), PCV15 (pneumococcal 15-valent conjugate vaccine), and PCV20 (pneumococcal 20-valent conjugate vaccine).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299892"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F210849"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Pneumococcal Vaccines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Conjugate Vaccine (13-Valent): Pneumococcal Polysaccharide Vaccine (23-Valent) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent).  Management: Administer PCV13 prior to administration of PPSV23. Immunocompetent patient with comorbidities: age 24 months to 71 months, separate by 8 weeks; age 65 years or older, separate by 1 year. Immunocompromised patient over age 24 months, separate by 8 weeks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Conjugate Vaccine (20-Valent): Pneumococcal Polysaccharide Vaccine (23-Valent) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (20-Valent). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Pneumococcal Vaccines. Management: Vaccination with inactivated vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during therapy, or for 6 weeks after completion of therapy. See full mono for recommendations for number, order, and timing of vaccines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Live/Attenuated): Pneumococcal Polysaccharide Vaccine (23-Valent) may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F210862"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Antibodies generated following PPSV23 vaccination of pregnant patients can be detected in cord blood (CDC/ACIP [Kobayashi 2023]).</p>
<p style="text-indent:0em;margin-top:2em;">Nonlive bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2023]). An increased risk of adverse pregnancy outcomes has not been observed following PPSV23 vaccination (CDC/ACIP [Kobayashi 2023]).</p>
<p style="text-indent:0em;margin-top:2em;">The immune response generated by the PPSV23 vaccine in pregnant patients is comparable to the immune response in patients who are not pregnant. Although specific recommendations for vaccination of pregnant patients is not available (CDC/ACIP [Kobayashi 2023]), pneumococcal vaccines may be administered during pregnancy in persons at increased risk of severe disease due to underlying medical conditions (ACOG 2018; ACOG 2022).</p></div>
<div class="block mopp drugH1Div" id="F53568406"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F210845"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal polysaccharide polyvalent is an inactive bacterial vaccine that induces active immunization to the serotypes contained in the vaccine. Although there are more than 90 known pneumococcal capsular types, pneumococcal disease is mainly caused by only a few serotypes of pneumococci. Pneumococcal vaccine polyvalent contains capsular polysaccharides of 23 pneumococcal types of <i>Streptococcus pneumoniae</i> that represent at least 85% to 90% of pneumococcal disease isolates in the US. The 23 capsular pneumococcal vaccine contains purified capsular polysaccharides of pneumococcal types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.</p>
<p style="text-indent:-2em;margin-left:2em;">Efficacy: In adults, PPSV23 demonstrated 50% to 80% efficacy in preventing invasive pneumococcal disease due to relevant serotypes of <i>S. pneumoniae</i> (CDC/ACIP 59[34] 2010).</p></div>
<div class="block phk drugH1Div" id="F26322291"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Immunity develops within approximately 2 to 3 weeks after vaccination (Pink Book [Atkinson 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Protective antibody levels persist for at least 5 years. A more rapid decline may occur in some groups (eg, children, elderly) (Pink Book [Atkinson 2012]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038770"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax 23 polyvalent</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Pneumorix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax ii</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax 23</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Pneumo 23</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pnu imune 23</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pneumovax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20498180">
<a name="20498180"></a>American Academy of Pediatrics Committee on Infectious Diseases, "Recommendations for the Prevention of <i>Streptococcus pneumoniae</i> Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)," <i>Pediatrics</i>, 2010, 126(1):186-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/20498180/pubmed" id="20498180" target="_blank">20498180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794683">
<a name="29794683"></a>American College of Obstetricians and Gynecologists (ACOG). Committee Opinion no. 741: maternal immunization. <i>Obstet Gynecol</i>. 2018;131(6):e214-e217. doi:10.1097/AOG.0000000000002662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/29794683/pubmed" id="29794683" target="_blank">29794683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). Maternal immunization practice advisory. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/10/maternal-immunization. Updated October 2022. Accessed December 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkinson.1">
<a name="Atkinson.1"></a>Atkinson W, Wolfe C, Hamborsky J, eds. Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book)</i>. 12th ed, second printing. Washington, DC: Public Health Foundation; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814406">
<a name="20814406"></a>Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). <i>MMWR Morb Mortal Wkly Rep</i>. 2010;59(34):1102-1106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/20814406/pubmed" id="20814406" target="_blank">20814406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23051612">
<a name="23051612"></a>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(40):816-819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/23051612/pubmed" id="23051612" target="_blank">23051612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm</a>. Updated October 12, 2012. Accessed August 27, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Pneumococcal Vaccination. <a href="https://www.cdc.gov/pneumococcal/vaccination.html" target="_blank">https://www.cdc.gov/pneumococcal/vaccination.html</a>. Updated January 20, 2023. Accessed June 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303‐306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7944842">
<a name="7944842"></a>Davidson M, Bulkow LR, Grabman J, et al, “Immunogenicity of Pneumococcal Revaccination in Patients With Chronic Disease,” <i>Arch Intern Med</i>, 1994, 154(19):2209-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/7944842/pubmed" id="7944842" target="_blank">7944842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102‐103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182599">
<a name="28182599"></a>Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/28182599/pubmed" id="28182599" target="_blank">28182599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26334788">
<a name="26334788"></a>Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(34):944-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/26334788/pubmed" id="26334788" target="_blank">26334788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37669242">
<a name="37669242"></a>Kobayashi M, Pilishvil T, Gierke R, et al. Pneumococcal vaccine for adults aged ≥ 19 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. <i>MMWR Morb Mortal Wkly Rep</i>. 2023;72(3):1-39. doi:10.15585/mmwr.rr7203a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/37669242/pubmed" id="37669242" target="_blank">37669242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed June 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31751323">
<a name="31751323"></a>Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices [published correction appears in <i>MMWR Morb Mortal Wkly Rep</i>. 2020;68(5152):1195]. <i>MMWR Morb Mortal Wkly Rep</i>. 2019;68(46):1069-1075. doi:10.15585/mmwr.mm6846a5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/31751323/pubmed" id="31751323" target="_blank">31751323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21150868">
<a name="21150868"></a>Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010;59(RR-11):1-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/21150868/pubmed" id="21150868" target="_blank">21150868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Pneumovax 23 (pneumococcal vaccine polyvalent) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.2">
<a name="Merck.2"></a>Pneumovax 23 (pneumococcal vaccine polyvalent) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.3">
<a name="Merck.3"></a>Pneumovax 23 (pneumococcal vaccine polyvalent) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” <i>Lancet</i>, 2009, 374(9698):1339-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25233284">
<a name="25233284"></a>Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(37):822-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pneumococcal-polysaccharide-vaccine-23-valent-ppsv23-pediatric-drug-information/abstract-text/25233284/pubmed" id="25233284" target="_blank">25233284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 12948 Version 189.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
